Related Experiment Video

Updated: Jun 19, 2026

Intrastriatal Injection of Autologous Blood or Clostridial Collagenase as Murine Models of Intracerebral Hemorrhage
09:41

Intrastriatal Injection of Autologous Blood or Clostridial Collagenase as Murine Models of Intracerebral Hemorrhage

Published on: July 3, 2014

14.7K

Plasma human cartilage glycoprotein-39 and depressive symptoms among acute ischemic stroke patients

Ziyi Wang1, Kaixin Zhang2, Chongke Zhong3

  • 1Department of Neurology, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong 226001, China.

General Hospital Psychiatry
|March 11, 2025
PubMed

Insights

Elevated plasma human cartilage glycoprotein-39 (YKL-40) levels are linked to a higher risk of depressive symptoms in acute ischemic stroke patients within three months. This finding suggests YKL-40 may serve as a potential biomarker for post-stroke depression.

Area of Science:

  • Neuroscience
  • Biochemistry
  • Clinical Medicine

Background:

  • Depressive symptoms frequently occur after acute ischemic stroke.
  • Identifying reliable biomarkers for post-stroke depression is crucial for timely intervention.
  • Human cartilage glycoprotein-39 (YKL-40) is implicated in inflammatory processes and neurological conditions.

Purpose of the Study:

  • To investigate the association between plasma YKL-40 levels and the presence of depressive symptoms at 3 months post-stroke.
  • To determine if YKL-40 can serve as a predictive marker for depressive symptoms in acute ischemic stroke survivors.

Main Methods:

  • Plasma YKL-40 levels were measured in 619 acute ischemic stroke patients from the CATIS trial.
  • Depressive symptoms were assessed at 3 months using the Hamilton Rating Scale for Depression (HRSD-24).
  • Statistical analyses, including quartile comparisons and dose-response modeling, were employed.

Main Results:

  • 39.1% of patients experienced depressive symptoms at 3 months.
  • Higher YKL-40 quartiles were significantly associated with an increased risk of depressive symptoms.
  • A dose-response relationship was observed, with each 1-SD increase in YKL-40 linked to a 32% higher risk.
  • YKL-40 improved the prediction and reclassification of depressive symptoms in risk models.

Conclusions:

  • Elevated plasma YKL-40 levels may indicate an increased risk for developing depressive symptoms 3 months after acute ischemic stroke.
  • YKL-40 shows potential as a novel biomarker for identifying patients at risk of post-stroke depression.
Abstract

Keywords:
BiomarkersDepressive symptomsIschemic strokeYKL-40

More Related Videos

A Middle Cerebral Artery Occlusion Technique for Inducing Post-stroke Depression in Rats04:38

A Middle Cerebral Artery Occlusion Technique for Inducing Post-stroke Depression in Rats

Published on: May 22, 2019

10.2K
A Model for Encephalomyosynangiosis Treatment after Middle Cerebral Artery Occlusion-Induced Stroke in Mice06:54

A Model for Encephalomyosynangiosis Treatment after Middle Cerebral Artery Occlusion-Induced Stroke in Mice

Published on: June 22, 2022

2.7K

Related Concept Videos

Acute Respiratory Failure-IV01:23

Acute Respiratory Failure-IV

Respiratory failure can manifest suddenly or gradually, characterized by a rapid decline in PaO2 and a rapid rise in PaCO2. This situation indicates a severe respiratory problem that may quickly become a life-threatening emergency. One of the early signs of hypoxemic Acute Respiratory Failure (ARF) is a change in mental status due to the brain's sensitivity to oxygen levels and changes in acid-base balance. Symptoms such as restlessness, confusion, and agitation suggest inadequate oxygen...
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
Psychoneuroimmunology: Diabetes and Cancer01:19

Psychoneuroimmunology: Diabetes and Cancer

Chronic stress has been linked to both the onset and progression of serious health conditions, including Type 2 diabetes and cancer. Type 2 diabetes, a widespread chronic illness, is closely associated with obesity and insulin resistance, both of which often worsen under stress. Studies indicate that men experiencing high levels of chronic stress face a 45% higher risk of developing diabetes compared to those with minimal stress. Stress triggers physiological responses that elevate blood...
Type I Diabetes III: Clinical Manifestations01:19

Type I Diabetes III: Clinical Manifestations

Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...
Hypoglycemia01:26

Hypoglycemia

Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...